Related Experiment Video
Updated: Jun 8, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Anticancer properties of zoledronic acid
1Novartis Pharma AG, Switzerland.
Abstract:
Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.
Insights
Zoledronic acid, used for bone cancer, shows potential anticancer effects by inhibiting tumor growth and spread. Further research is ongoing to understand its role in cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Zoledronic acid is established in managing skeletal-related events in metastatic bone cancer.
- Emerging evidence suggests potential direct anticancer activities of zoledronic acid.
Purpose of the Study:
- To explore the anticancer properties of zoledronic acid beyond its skeletal benefits.
- To investigate the mechanisms by which zoledronic acid may inhibit cancer progression.
Main Methods:
- Review of preclinical data from animal models involving zoledronic acid and anticancer therapies.
- Analysis of in vitro studies examining zoledronic acid's effects on tumor cells.
- Evaluation of early clinical data on zoledronic acid in cancer patients.
Main Results:
- Preclinical studies demonstrate zoledronic acid's ability to inhibit soft-tissue tumor growth, proliferation, and angiogenesis.
- Zoledronic acid treatment in models also showed increased apoptosis, altered macrophage function, and enhanced immune surveillance.
- In vitro and pilot clinical data suggest zoledronic acid may inhibit tumor cell dissemination and improve patient outcomes.
Conclusions:
- Zoledronic acid exhibits promising anticancer properties, including inhibition of tumor growth, metastasis, and enhancement of anti-tumor immunity.
- The drug may play a significant role in improving outcomes for cancer patients, warranting further investigation.
- Ongoing clinical trials are crucial to fully establish the therapeutic potential of zoledronic acid in oncology.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity

